Noninvasive Predictors of High-Risk Varices in Patients with Non-Cirrhotic Portal Hypertension
- PMID: 30881946
- PMCID: PMC6383430
- DOI: 10.1155/2019/1808797
Noninvasive Predictors of High-Risk Varices in Patients with Non-Cirrhotic Portal Hypertension
Abstract
Non-cirrhotic portal hypertension (NCPH) comprises a heterogeneous group of liver disorders causing portal hypertension without cirrhosis and carries a high risk of variceal bleeding. Recent guidelines, based largely on patients with viral cirrhosis, suggest low likelihood of high risk varices (HRV) in patients with a liver stiffness measurement (LSM) <20 kPa and platelet count >150 × 109/L. In NCPH, LSM is often higher than healthy controls but lower than matched cirrhotic patients. The aim of this study was to assess whether LSM or other noninvasive assessments of portal hypertension could predict HRV in NCPH patients. Methods. Records of patients with NCPH seen at a single centre between 2007 and 2018 were reviewed retrospectively. Primary outcome measure was presence or absence of HRV at gastroscopy within 12 months of clinical assessment. Association of LSM or other clinical features of portal hypertension (spleen size, platelet count, platelet count/spleen length ratio (PSL), LSM-spleen length/platelet count ratio score (LSP)) with HRV and ability of these variables to predict HRV was analysed. Results. Of 44 patients with NCPH who met inclusion criteria, 34% (15/44) had HRV. In a multivariate model, spleen size and PSL correlated with HRV but platelet count, LSM, and LSP did not (spleen size: β = 0.35, p = 0.02; OR 1.42, 95% CI 1.06-1.92; PSL: β = -1.47, p = 0.02; OR 0.23, 95% CI 0.07-0.80). There was no significant difference between spleen size and PSL in predicting HRV (AUROC 0.81 (95% CI 0.66 - 0.91) versus 0.71 (95% CI 0.54 - 0.84), respectively, p = 0.400). Spleen size >17.2cm had sensitivity 78.6% and specificity 64.3% for prediction of HRV. Conclusions. In NCPH patients, spleen size may predict risk of HRV at gastroscopy within 12 months. LSM and platelet count are not useful to assess risk of HRV in NCPH.
Figures


Similar articles
-
Transient splenic elastography predicts high-risk esophageal varices in patients with non-cirrhotic portal hypertension.Scand J Gastroenterol. 2021 Dec;56(12):1462-1466. doi: 10.1080/00365521.2021.1968485. Epub 2021 Aug 24. Scand J Gastroenterol. 2021. PMID: 34428123
-
Spleen and Liver Stiffness Is Positively Correlated with the Risk of Esophageal Variceal Bleeding.Digestion. 2016;94(3):138-144. doi: 10.1159/000450704. Epub 2016 Oct 19. Digestion. 2016. PMID: 27756066
-
A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease.J Hepatol. 2018 Aug;69(2):308-317. doi: 10.1016/j.jhep.2018.04.023. Epub 2018 May 3. J Hepatol. 2018. PMID: 29729368
-
Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding.Liver Int. 2017 May;37(5):707-716. doi: 10.1111/liv.13318. Epub 2016 Dec 6. Liver Int. 2017. PMID: 27862856 Review.
-
Computed tomography vs liver stiffness measurement and magnetic resonance imaging in evaluating esophageal varices in cirrhotic patients: A systematic review and meta-analysis.World J Gastroenterol. 2020 May 14;26(18):2247-2267. doi: 10.3748/wjg.v26.i18.2247. World J Gastroenterol. 2020. PMID: 32476790 Free PMC article.
Cited by
-
Spleen stiffness measurement as a non-invasive assessment in patients with portal hypertension.eGastroenterology. 2024 Feb 17;2(1):e100031. doi: 10.1136/egastro-2023-100031. eCollection 2024 Jan. eGastroenterology. 2024. PMID: 39944747 Free PMC article. Review.
-
Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis.J Liver Cancer. 2024 Mar;24(1):81-91. doi: 10.17998/jlc.2023.12.25. Epub 2024 Jan 19. J Liver Cancer. 2024. PMID: 38246747 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous